Treatment of Lennox-Gastaut syndrome: Overview and recent findings

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1001-1019

  van Rijckevorsel, Kenou ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Epileptic encephalopathies; Lennox Gastaut syndrome; LGS; Refractory; Surgery; Treatment; VNS

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BROMIDE; CARBAMAZEPINE; CINROMIDE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETIRACETAM; FELBAMATE; FLUNARIZINE; GABAPENTIN; IMMUNOGLOBULIN G; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; NITRAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RUFINAMIDE; SUCCINIMIDE DERIVATIVE; SV 2A; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ADJUVANT THERAPY; APLASTIC ANEMIA; ATAXIA; BRAIN DEPTH STIMULATION; BRAIN SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CORPUS CALLOSUM TRANSSECTION; COUGHING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DROWSINESS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTIC STATE; FATIGUE; GAMMA KNIFE RADIOSURGERY; GLAUCOMA; HUMAN; IMMUNOTHERAPY; INCIDENCE; IRRITABILITY; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LIVER FAILURE; MAGNETOENCEPHALOGRAPHY; MENTAL DETERIORATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE INFECTION; POSTOPERATIVE PAIN; PREVALENCE; PROGNOSIS; REVIEW; SEDATION; SEIZURE; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; SWEATING; TREMOR; VAGUS NERVE STIMULATION; VISUAL DISORDER; VOICE CHANGE; WEIGHT REDUCTION;

EID: 60249089708     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (223)

1. Aarli JA. 2000. Epilepsy and the immune system. Arch Neurol, 57:1689-92.
2. Aarli JA, Fontana A. 1980. Immunological aspects of epilepsy. Epilepsia, 21:451-7.
3. Al Ajlouni S, Shorman A, Daoud AS. 2005. The efficacy and side effects of topiramate on refractory epilepsy in infants and young children: a multi-center clinical trial. Seizure, 14:459-63.
4. Aldenkamp AP, Majoie HJ, Berfelo MW, et al. Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome. Epilepsy Behav, 3:475-9.
5. Alexopoulos AV, Kotagal P, Loddenkemper T, et al. 2006. Long-term results with vagus nerve stimulation in children with pharmacoresistant epilepsy. Seizure, 15:491-503.
6. Alva-Moncayo E, Ruiz-Ruiz A. 2003. The value of topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox-Gastaut syndrome. Revista de Neurologia, 36:453-7.
7. Angelini L, Broggi G, Riva D, et al. 1979. A Case of Lennox-Gastaut Syndrome Successfully Treated by Removal of a Parietotemporal Astrocytoma. Epilepsia, 20:665-9.
8. Arcas J, Ferrer T, Roche MC, et al. 2001. Hypohidrosis related to the administration of topiramate to children. Epilepsia, 42:1363-5.
9. Ariizumi M, Baba K, Shiihara H, et al. 1983. High dose gammaglobulin for intractable childhood epilepsy. Lancet, 2:162-3.
10. Arroyo S. 2007. Rufinamide. Neurotherapeutics, 4:155-62.
11. Avanzini G, Canger R, Dalla Bernardina B, et al. 1996. Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian study group. Epilepsy Res, 25:249-55.
12. Banta JT, Hoffman K, Budenz DL, et al. 2001. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol, 132:112-4.
13. Battaglia A, Ferrari AR, Guerrini R. 1991 Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy. Brain Dev, 13:217-22.
14. Ben-Menachem E, Hellstrom K, Waldton C, et al. 1999. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. Neurology, 52:1265-7.
15. Bennett B, Matagne A, Michel P, et al. 2007. Seletracetam (UCB 44212). Neurotherapeutics, 4:117-22.
16. Bialer M, Johannessen SI, Kupferberg H J, et al. 2007. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res, 73:1-52.
17. Billiau AD, Wouters CH, Lagae LG. 2005. Epilepsy and the immune system: is there a link? Eur J of Ped Neurol, 9:29-42.
18. Billiau AD, Witters P, Ceulemans B, et al. 2007. Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile. Epilepsia, 48:1739-49.
19. Blume WT. 2004. Lennox-Gastaut syndrome: potential mechanisms of cognitive regression. Ment Retard Dev Disabil Res Rev, 10:150-3.
20. Browne TR. Other succinimides: methsuximide. 1995. In: Levy RH, Mattson RH, Meldrum BS (eds). Antiepileptic Drugs. 4th ed. New York: Raven Press: Publisher. p. 681-7.
21. Camfield P, Camfield C. 2007. Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study. Epilepsia, 48:1128-32.
22. Chamberlain MC. 1996. Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome. J Child Neurol, 1:31-4.
23. Cianchetti C, Pruna D, Coppola G, et al. 2002. Low-dose lamotrigine in West syndrome. Epilepsy Res, 51:199-200.
24. Chiron C. 2007. Stiripentol. Neurotherapeutics, 4:123-5.
25. Chung SY, Han SH. 2003. Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. J Pineal Res, 34:95-102.
26. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. 1989. Epilepsia, 30:389-99.
27. Conry JA. 2004. Pharmacologic treatment of the catastrophic epilepsies. Epilepsia, 45(S5): 12-6.
28. Coppola G, Caliendo G, Veggiotti P, et al. 2002. Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res, 51:147-53.
29. Cukiert A, Burattini JA, Mariani PP, et al. 2006. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia, 47:371-4.
30. Dan B, Boyd SG. 2005. Nonconvulsive (dialeptic) status epilepticus in children. Current Pediatric Reviews, 1:7-16.
31. Delanty N, French J. 1998. Treatment of Lennox-Gastaut syndrome: current recommendations. CNS Drugs, 10:181-8.
32. De Los Reyes EC, Sharp GB, Williams JP, et al. 2004. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol, 30:254-6.
33. DeMarco P, Zagnoni P. 1986. Allopurinol and severe epilepsy. Neurology, 36:1538-9.
34. De Vivo DC, Trifiletti RR, Jacobsen RI, et al. 1991. Defective glucose transport across the blood-brain-barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med, 325:703-9.
35. Dichter MA, Cole AJ. 2002. Neuroprotection and antiepileptogenesis: where are we now? Neurology, 59(9S5):S36-S38.
36. Dimario FJ, Clancy RR. 1988. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pedriatr Neurol, 4:249-51.
37. Dodson WE. 1993. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia, 34(S7):S18-S24.
38. Donaldson JA, Glauser TA, Olberding LS. 1997. Lamotrigine Adjunctive Therapy in Childhood Epileptic Encephalopathy (the Lennox Gastaut Syndrome). Epilepsia, 38:68-73.
39. Dulac O, Chiron C, Luna D, et al. 1991. Vigabatrin in childhood epilepsy. J Child Neurol, 6:S30-S37.
40. Dulac O, Kaminska A. 1997. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol, 12(S1):S23-S28.
41. Dulac O. 2001. Epileptic encephalopathy. Epilepsia, 42(S3):23-6.
42. Dulac O, Engel J. 2005. URL: http://www.ilaeepilepsy.org/Visitors/Centre/ ctf/lennox_gastaut.cfm.
43. Duse M, Notarangelo LD, Tiberti S, et al. 1996. Intravenous immune globulin in the treatment of intractable childhood epilepsy. Clin Exp Immunol, 104(S1):71-6.
44. Echenne B, Dulac O, Parayre-Chanez MJ, et al. 1991. Treatment of infantile spasms with intravenous gamma-globulins. Brain Dev, 13:313-9.
45. Eder HG, Feichtinger M, Pieper T, et al. 2006. Gamma Knife radiosurgery for callosotomy in children with drug-resistant epilepsy. Childs Nerv Syst, 22:1012-7.
46. EMEA report 2007. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ diacomit/H-664-en6.pdf.
47. Engel J. 2001. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy. Report of the ILAE Task Force on Classification and Terminology. Epilepsia, 42:796-803.
48. Eriksson AS, Nergardh A, Hoppu K. 1998. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia, 39:495-501.
49. Espinosa Zacarias J, Gutierrez Moctezuma J, Villegas Pena H, et al. 2002. Intravenous treatment with immunoglobulins in epileptic syndromes which are difficult to control. Rev Neurol, 34:816-9.
50. Farrell K. 1986. Benzodiazepines in the treatment of children with epilepsy. Epilepsia, 27(S1):S45-S52.
51. Farrell K, Connolly MB, Munn R, et al. 1997. Prospective, open-label, add-on study oflamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol, 16:201-5.
52. Farrell K. 2002. Drug therapy in Lennox-Gastaut syndrome. Adv Exp Med Biol, 77:486-97.
53. Farwell JR, Anderson GD, Kerr BM, et al. 1993. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia, 34:305-11.
54. Feasby T, Banwell B, Benstead T, et al. 2007. Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions. Transfus Med Rev, 21(2,S1):S57-S107.
55. Feichtinger M, Schröttner O, Eder H, et al. 2006. Efficacy and safety of radiosurgical callosotomy: a retrospective study. Epilepsia, 47:1184-91.
56. Felbamate Study Group in Lennox-Gastaut Syndrome. 1993. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med, 328:29-33.
57. Ferric CD, Maisey M, Cox T, et al. 1996. Focal abnormalities detected by 18FDG PET in epileptic encephalopathies. Arch Dis Child, 75:102-7.
58. Feucht M, Brantner-Inthaler S. 1994. Gamma-vinyl-GABA (vigabatrin) in the therapy of Leunox-Gastaut syndrome: an open study. Epilepsia, 35:993-8.
59. Fois A, Vascotto M. 1990. use of intravenous immunoglobulins in drug-resistant epilepsy. Childs Nerv Syst, 6:400-5.
60. Freeman JM, Vining EPG, Pillas DJ, et al. 1998. The efficacy of the ketogenic diet - 1998: a prospective evaluation of intervention in 150 children. Pediatrics, 102:1358-63.
61. Freeman JM, Vining PG. 1999. Seizures decrease rapidly after fasting. Preliminary studies of the ketogenic diet. Arch Pediatr Adolesc Med, 153:946-9.
62. Freese A, Kaplitt MG, O'Connor WM, et al. 1997. Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implications for a gene therapy approach to epilepsy. Epilepsia, 38:759-66.
63. French J, A.M. Kanner AM, Bautista J, et al. 2004. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 62:1261-73.
64. Frost M, Gates J, Helmers SL et al. 2001. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia, 42:1148-52.
65. Garland H, Sumner D. 1964. Sulthiame in treatment of epilepsy. Br Med J, 1:474-6.
66. Gastaut H, Roger J, Soulayrol R, et al. 1966. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as "Petit mal variant") or Lennox syndrome. Epilepsia, 7:139-79.
67. Gay PE, Mecham GF, Coskey JS, et al. 1995. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Psychol Rep, 77:1208-10.
68. Genton P, Guerrini R, Dravet C. 2000. The Lennox-Gastaut syndrome. In: Meinardi H. ed. Handbook of Clinical Neurology, Vol. 73 (29): The Epilepsies, Part II. Amsterdam: Elsevier: Publisher. p. 211-22.
69. Gibbs FA, Gibbs EL, Lennox WG. 1939. Influence of blood sugar level on wave and spike formation in petit mal epilepsy. Arch Neurol Psychiatry, 41:1111.
70. Glauser TA, Sachdeo RC, Ritter FJ, et al. 1997. Topiramate as adjunctive therapy in Leunox-Gastaut syndrome. Epilepsia, 38:207.
71. Glauser TA. 1998. Topiramate use in pediatric patients. Can J Neurol Sci, 39:874-7.
72. Glauser TA, Levisohn PM, Ritter F, et al. 2000. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia, 41(S1):S86-S90.
73. Glauser TA, Pellock JM. 2002. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol, 17:87-96.
74. Glauser TA. 2004. Following catastrophic epilepsy patients from childhood to adulthood. Epilepsia, 45(S5):23-6.
75. Glauser T, Kluger G, Sachedo R, et al. 2005. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology, 64:1826.
76. Goldsmith IL, Zupanc ML, Buchhalter JR. 2000. Long-term seizure oucome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic group. Epilepsia, 41:3954.
77. Gross-Tsur V, Shalev RS, Kazir E, et al. 1993. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand, 88:204-9.
78. Guerreiro MM, Manreza ML, Scotoni AE, et al. 1999. A pilot study of topiramate in childen with Lennox-Gastaut syndrome. Arq Neuropsiquiatr, 57:167-75.
79. Gur RC, Sussman NM, Alavi A, et al. 1982. Positron emission tomography in two cases of childhood epileptic encephalopathy (Lennox-Gastaut syndrome) Neurology, 32:1191.
80. Hakimian S, Cheng-Hakimian A, Anderson GD, et al. 2007. Rufinamide: a new anti-epileptic medication. Exp Opin Pharmacother, 8:1931-40.
81. Han SH, Chung SY. 2000. Melatonin attenuates trimethyltin-induced hippocampal neurodegeneration Neurobiology of Aging, 21 (S1):226.
82. Hancock E, Cross H. 2003. Treatment of Lennox-Gastaut syndrome. Cochrane Database of Systematic Reviews, Issue 3. Art. No: CD003277. DOI: 10.1002/14651858.CD003277.
83. Hartman AL, Vining EP. 2007. Clinical aspects of the ketogenic diet. Epilepsia, 48:31-42.
84. Heiskala H. 1997. Community-based study of Lennox-Gastaut syndrome. Epilepsia, 38:526-31.
85. Hemingway C, Freeman JM, Pillas DJ, et al. 2001. The ketogenic diet: a 3 to 6 year follow-up of 150 children enrolled prospectively. Pediatrics, 108:898-905.
86. Henderson CB, Filloux FM, Alder SC, et al. 2006. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol, 21:193-8.
87. Holowich J, Thurston DL. 1958. A clinical evaluation of acetazolamide (Diamox) in the treatment of epilepsy in children. J Pediatr, 53:160-71.
88. Hornig GW, Murphy JV, Shallert G, et al. 1997. Left vagus nerve stimulation in children with refractory epilepsy: an update. South Med J, 90:484-8.
89. Hosain S, Nikalov B, Harden C, et al. 2000. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol, 15:509-12.
90. Hosain SA, Green NS, Solomon GE, et al. 2003. Nitrazepam for the treatment of Lennox-Gastaut syndrome. Pediatr Neurol, 28:16-9.
91. Ilium N, Taudorf K, Heilmann C, et al. 1990. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics, 21:87-90.
92. Inanaga K, Kumashiro H, Fukyama Y, et al. 1989. Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy. Epilepsia, 30:438-45.
93. Jeavons PM, Clark JE, Maheshwari MC. 1977. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ("Epilim"). Dev Med Child Neurol, 19:9-25.
94. Jensen PK. Felbamate in the treatment of Lennox-Gastaut syndrome. 1994. Epilepsia, 35(S5):S54-S7.
95. Jensen FE. 2006. Pediatric epilepsy model. Epilepsy Res, 68:28-31.
96. Johannessen CU, Johannessen SI. 2003. Valproate: past, present, and future. CNS Drug Rev, 9:199-216.
97. Kaminski RM, Matagne A, Leclercq K, et al. 2008. SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, 54:715-20.
98. Karceski S. 2001. Vagus nerve stimulation and Lennox-Gastaut syndrome: a review of the literature and data from the VNS patient registry. CNS Spectrum, 6:766-67.
99. Klein R, Livingston S. 1950. The effect of adrenocorticotrophic hormone in epilepsy, J Pediatr, 37:733-42.
100. Kinsman SL, Vining EP, Quaskey SA, et al. 1992. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia, 33:1132-6.
101. Kluger G, Bauer B. 2007. Role of Rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat, 3:3-11.
102. Kulig K, Malawska B. 2007. Carisbamate, a new carbamate for the treatment of epilepsy. Idrugs, 10:720-7.
103. Kwan SY, Lin JH, Wong TT, et al. 2006. A comparison of seizure outcome after callosotomy in patients with Lennox-Gastaut syndrome and a positive or negative history for West syndrome. Seizure, 15:552-7.
104. Labar D, Nikolov B, Tarver B, et al. 1998. Vagus nerve stimulation for symptomatic generalized epilepsy: a pilot study. Epilepsia, 39:201-5.
105. Labate A, Colosimo E, Gambardella A, et al. 2006. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure, 15:214-8.
106. Laxer K, Blum D, Abou-Khalil BW, et al. 2000. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group, Epilepsia, 41:1187-94.
107. Leary LD, Wang D, Nordli Jr DR, et al. 2003. Seizure characterization and electroencephalographic features in Glut-1 deficiency syndrome. Epilepsia, 44:701-7.
108. Lee YM, Kang HC, Lee JS, et al. 2008. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia, 49:685-90.
109. Lefevre F, Aronson N. 2000. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics, 105:E46.
110. Lennox WG. 1945. The petit mal epilepsies; their treatment with tridione. JAMA, 129:1069-74.
111. Lennox WG, Davis JP. 1950. Clinical correlates of the fast and the slow spike-wave electroencephalogram. Pediatrics, 5:626-44.
112. Lerman P, Nussbaum E. 1975. The use of sulthiame- in myoclonic epilepsy of childhood and adolescence. Acta Neurol Scand Suppl, 60:7-12.
113. Levy R, Cooper P. 2003. Cochrane Database of Systematic Reviews (3):CD001903.
114. Liske E, Forster FM. 1963. Clinical evaluation of the anticonvulsant effects of sulthiame. J New Drugs, 3:32-6.
115. Liu S, An N, Yang H, et al. 2007. Pediatric intractable epilepsy syndromes: Reason for early surgical intervention. Brain Dev, 29:69-78.
116. Livingston JH, Beaumont D, Arzimanoglou A, et al. 1989. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol, 27:109s-112s.
117. Lockman LA, Rothner AD, Erenberg G, et al. 1980. Cinromide in the treatment of seizures in the Lennox-Gastaut syndrome. Epilepsia, 22:241(Abstract).
118. Lombroso CT, Davidson DTJ, Gross-Bianchi ML. 1956. Further evaluation of acetazolamide (Diamox) in treatment of epilepsy. JAMA, 160:268-72.
119. Lombroso CT, Forsythe I. 1960. A long-term follow-up of acetazolamide (Diamox) in the treatment of epilepsy. Epilepsia, 1:493-500.
120. Luna D, Dulac O, Pajot N, et al. 1989. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia, 30:430-7.
121. Lundgren J, Amark P, Blennow G, et al. 1998. Vagus nerve stimulation in 16 children with refractory epilepsy. Epilepsia, 39:809-13.
122. Machara T, Shimizu H, Oda M, et al. 1996. Surgical treatment of children with medical intractable epilepsy: outcome of various surgical procedures. Neurol Med Chi, 36:205-309.
123. Majoie HJ, Berfelo MW, Aldenkamp AP, et al. 2001. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol, 18:419-28.
124. Małek R, Borowicz KK, Kimber-Trojnar Z, et al. 2003. Remacemide - a novel potential antiepileptic drug. Pol J Pharmacol, 55:691-8.
125. Manthey D, Asimiadou S, Stefovska V, et al. 2005. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol, 193:497-503.
126. Marrosu F, Marrosu G, Rachele MG, et al. 1990. Allopurinol add-on treatment in intractable seizures. Acta Neurol (Napoli), 12:207-13.
127. Mikaeloff Y, de Saint-Martin A, Mancini J, et al. 2003. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res, 53:225-32.
128. Modur PN, Milteer WE. 2008. Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy. Epilepsy Behav, 13:397-401.
129. Monaghan EP, Navalta LA, Shum L, et al. 1997. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia, 38:1026-31.
130. Morrell F, Whisler WW, Bleck TP. 1989. Multiple subpial transection: a new approach to the surgical treatment of focal epilepsy. J Neurosurg, 70:231-9.
131. Motte J, Trevathan E, Arvidsson JF, et al. 1997. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med, 337:1807-12.
132. Muller K, Lenard HG. 1988. The Lennox-Gastaut syndrome: therapeutic aspects including dietary measures and general management. In: Niedermeyer E, Degen D, eds. The Lennox-Gastaut syndrome. New York: Alan R. Liss, Publisher, p. 341-55.
133. Munn R, Farrell K. 1993. Open study of clobazam in refractory epilepsy. Pediatr Neurol, 9:465-9.
134. Naidu S, Gruener G, Brazis P. 1986. Excellent results with clorazepate in recalcitrant childhood epilepsies. Pediatr Neurol, 2:18-22.
135. Ng YT, Collins SD. 2007. Clobazam. Neurotherapeutics, 4:138-44.
136. Niedermeyer E. 1969. The Lennox-Gastaut syndrome, a severe type of childhood epilepsy. Dtsch Z Nervenheilk, 195:263-82.
137. Noe F, Nissinen J, Pitkänen A, et al. 2007. Gene therapy in epilepsy: The focus on NPY. Peptides, 28:377-83.
138. Nordgren RE, Reeves AG, Viguera AC et al. 1991. Corpus callosotomy for intractable seizures in the pediatric age group. Arch Neurol, 48:364-72.
139. Orange JS, Hossny EM, Weiler CR, et al. 2006. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Journal of Allergy and Clinical Immunology, 117(4 S1):S525-S553.
140. Patil AA, Andrews RV, Johnson M, et al. 2004. Is epilepsy surgery on both hemispheres effective? Stereotact Funct Neurosurg, 82:214-21.
141. Patwardhan RV, Stong B, Bebin EM, et al. 2000. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. Neurosurgery, 47:1353-1357; discussion 1357-8.
142. Parker AP, Polkey CE, Binnie CD, et al. 1999. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics, 103:778-82.
143. Pechadre JC, Sauvezie B, Osier C, et al. 1977. Traitement des encéphalopathies épileptiques de l'enfant par les gammaglobulines. Rev EEG Neurophysiol Clin, 7:443-7.
144. Peled N, Shorer Z, Peled E, et al. 2001. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia, 42:1208-10.
145. Pellock JM, Faught E, Leppik IE, et al. 2006. Felbamate: consensus of current clinical experience. Epilepsy Res, 71:89-101.
146. Pendl G, Eder HG, Schroettner O, et al. 1999. Corpus callosotomy with radiosurgery. Neurosurgery, 45:303-7.
147. Perucca E, Gram L, Avanzini G, et al. 1998. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia, 39:5-17.
148. Perucca E, French J, Bialer M. 2007. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol, 6:793-804.
149. Perucca E, Cloyd J, Critchley D, et al. 2008. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy: Epilepsia, 49:1123-41.
150. Peters DH, Sorkin EM. 1993. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs, 45:760-87.
151. Pieribone VA, Tsai J, Soufflet C, et al. 2007. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia, 48:1870-4.
152. Pinder RM, Brogden RN, Speight TM, et al. 1976. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs, 12:321-61.
153. Purves SJ, Wada JA, Woodhurst WB, et al. 1988. Results of anterior corpus callosum section in 24 patients with medically intractable seizures. Neurology, 38:1194-201.
154. Quarato PP, Gennaro GD, Manfredi M, et al. 2002. Atypical Lennox-Gastaut syndrome successfully treated with removal of a parietal dysembryoplastic tumour. Seizure, 11:325-9.
155. Quilichini PP, Chiron C, Ben-Ari Y, et al. 2006. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia, 47:704-16.
156. Rathore C, Abraham M, Rao RM, et al. 2007. Outcome after corpus callosotomy in children with injurious drop attacks and severe mental retardation. Brain Dev, 29:577-85.
157. Reutens DC, Bye AM, Hopkins IJ, et al. 1993. Corpus callosotomy for intractable epilepsy: seizure outcome and prognostic factors. Epilepsia, 34:904-9.
158. Ritter FJ, Glauser TA, Sachdeo RC, et al. 1998. Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia, 39(S2):2-3.
159. Roecklein BA, Sacks HJ, Mortko H, et al. 2007. New Antiepileptic Drugs: Discovery, Development, and Update. Part 2: Progress in current AED development: The drugs. Fluorofelbamate. Neuro Therapeutics, 4:97-101.
160. Rogawski MA. 2006. Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res, 69:273-94.
161. Roger J, Dravet C, Bureau M. 1989. The Lennox-Gastaut syndrome. Cleve Clin J Med, 56(S2):S172-80.
162. Rougier A, Claverie B, Pedespan JM, et al. 1997. Callosotomy for intractable epilepsy: overall outcome. J Neurosurg Sci, 41:51-7.
163. Rychlicki F, Zamponi N, Trignani R, et al. 2006. Vagus nerve stimulation: clinical experience in drug-resistant pediatric epileptic patients. Seizure, 15(7):483-90
164. Sachdeo R, Kugler S, Wenger E, et al. 1996. Topiramate in Lennox-Gastaut syndrome. Epilepsia, 37(S4):118.
165. Sachdeo RC, Glauser TA, Ritter R, et al. 1999. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology, 52:1882-7.
166. Sakurai K, Tanaka N, Kamada K, et al. 2006. Magnetoencephalographic studies of focal epileptic activity in three patients with epilepsy suggestive of Lennox-Gastaut syndrome. Epileptic Disord, 9:158-63.
167. Santos CC, Brotherton T. 2005. Use of zonisamide in pediatric patients. Pediatr Neurol, 33:12-4.
168. Sazgar M, Bourgeois BF. 2005. Aggravation of epilepsy by antiepileptic drugs. Pediatric Neurology, 33:227-34.
169. Schmidt D, Bourgeois B. 2000. A risk-benefit assessment of therapies for Lermox-Gastaut syndrome. Drug Saf, 22:467-77.
170. Schlumberger E, Chavez F, Palacios L, et al. 1994. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia, 35:359-67.
171. Scott RC, Besag FM, Neville BG. 1999. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet, 353:623-6.
172. Siegel H, Kelley K, Stertz B, et al. 1999. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res, 34:91-7.
173. Sinclair DB. 2003. Prednisone therapy in pediatric epilepsy. Pediatr Neurol, 28:194-8.
174. Sorel L, Dusaucy-Bauloye A. 1958. Apropos de 21 cas d'hypsarrhythmia de Gibbs: Son traitement spectaculaire par I'ACTH. Acta Neurol Belg, 58:130-41.
175. Spencer SS, Schramm J, Wyler A, et al. 2002. Multiple subpial transection for intractable partial epilepsy: an international meta-analysis. Epilepsia, 43:141-5.
176. Stêpieñ K, Tomaszewski M, Czuczwar SJ. 2005. Profile of anticonvulsant activity and neuroprotective effects of novel and potential antiepileptic drugs - an update. Pharmacological Reports, 57:719-33.
177. Sterio M, Gebauer E, Felle D, et al. 1992. Malignant epilepsy in children: therapy with high doses of intravenous immunoglobulin. Med Pregl, 45:220-4.
178. Swink TD, Vining EP, Freeman JM. 1997. The ketogenic diet: 1997. Adv Pediatr, 44:297-329.
179. Tanabe T, Awaya Y, Matsuishi T, et al. 2008. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome) - A nationwide questionnaire survey in Japan. Brain Dev, Available online 17 April 2008.
180. Tartara A, Sartori I, Manni R, et al. 1996. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurol Sci, 17:429-32.
181. Tassinari CA, Dravet C, Roger J, et al. 1972. Tonic status epilepticus precipitated by intravenous benzodiazepines in five patients with Lennox-Gastaut syndrome. Epilepsia, 13:421-35.
182. Technology Evaluation Center. 2003. MEG ans MSI: Presurgical localization of epileptic lesions and presurgical function mapping. Assessment Program, 18:1-27.
183. The Group for the evaluation of cinromide in the Lennox-Gastaut syndrome. 1989. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia, 30:422-9.
184. Timmings PL, Richens A. 1992. Lamotrigine as add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol, 32:305-7.
185. Tran A, Vauzelle-Kervroëdan F, Rey E, et al. 1996. Effect of stiripentol on CBZ plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol, 50:497-500.
186. Trevathan E, Murphy CC, Yeargin-Allsopp M. 1997. Prevalence and descriptive epidemiology of Lermox-Gastaut syndrome among Atlanta children. Epilepsia, 38(12): 1283-8.
187. Trimble MR. 2002. On the use of tranquillisers in epilepsy. Epilepsia, 43(S2):25-7.
188. Uvebrant P, Bauzienè R. 1994. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatries, 25:284-9.
189. Vajda FJ, Bladin PF, Parsons BJ. 1985. Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clin Exp Neurol, 21:177-82.
190. van Engelen BG, Renier WO, Weemaes CM, et al. 1994a. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome: an add-on study. Eur J Pediatr, 153:762-9.
191. van Engelen BG, Renier WO, Weemaes CMR, et al. 1994b. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Research, 19:181-90.
192. van Rijckevorsel K, Delire M, Rucquoy-Ponsar M. 1986. Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins. Eur Arch Psych Clin Neuroscience, 236:119-22.
193. van Rijckevorsel K, Delire M, Schmitz-Moorman W, et al. 1994. Treatment of refractory epilepsy with intraveinous immunoglobulins. Results of the first double blind/dose finding clinical study. Intern J Clin Lab Res, 24:162-6.
194. van Rijckevorsel K. 1999. Immunological mechanisms in the aetiology of epilepsy. Implications for treatment. Biodrugs, 12:115-27.
195. van Rijckevorsel K, de Tourtchaninoff M, van Raay Y, et al. 2006. Multiple subpial transsections: safety and evolution of 30 patients. Epilepsia, 47(S3):4-5.
196. Van Wagenen WP, Herren RY. 1940. Surgical division of commissural pathways and the corpus callosum: relation to spread of an epileptic attack. Arch Neurol Psychiatry, 44:740-59.
197. Vassella F, Pavlincova E, Schneider HJ, et al. 1973. Treatment of infantile spasms and Lennox-Gastaut syndrome with clonazepam (Rivotril). Epilepsia, 14:165-75.
198. Vassella F, Rudeberg A, Da Silva V, et al. 1978. Double-blind study of the anticonvulsive effect of Phenobarbital and valproate in the Lennox syndrome. (Doppelblind Untersuchung uber die anticonvulsive Wirkung von Phenobarbital and Valproat beim Lennox-Gastaut Syndrom). Schweiz Med Wochenschr, 108:713-6.
199. Vaz G, van Raay Y, van Rijckevorsel K, et al. 2008. [Safety and efficacy of multiple subpial transections: report of a consecutive series of 30 cases]. Neurochirurgie, 54:311-4.
200. Velasco M, Velasco F, Alcala H, et al. 1991. Epileptiform EEG activity of the centromedian thalamic nuclei in children with intractable generalized seizures of the Lennox-Gastaut syndrome. Epilepsia, 32:310-21.
201. Velasco F, Velasco M, Velasco AL, et al.1993. Effect of chronic electrical stimulation of the centromedian thalamic nuclei on various intractable seizure patterns, I: clinical seizures and paroxysmal EEG activity. Epilepsia, 34:1052-64.
202. Velasco AL, Velasco F, Jimenez F, et al. 2006. Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome. Epilepsia, 47:1203-12.
203. Verhelst H, Boon P, Buyse G, et al. 2005. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure, 14:412-21.
204. Vining EP, Freeman JM, Ballaban-Gil K, et al. 1998. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol, 55:1433-7.
205. von Rosenstiel P. 2007. Brivaracetam (UCB 34714). Neurotherapeutics, 4:84-7.
206. Vossler DG. 1996. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology, 46:852-3.
207. Wang D, Pascual JM, Engelstad K, et al. 2005. Glut-I deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol, 57:111-8.
208. Weber S, Beran RG. 2004. A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. J Clin Neurosci, 11:728-31.
209. Wexler ID, Hemalatha SG, Mc Connell J, et al. 1997. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology, 49:1655-61.
210. Wheless JW, Clarke DF, Carpenter D. 2005. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol, 20(S1):S1-S56.
211. White HS, Smith MD, Wilcox KS. 2007. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol, 81:85-110.
212. Woody RC. 1990. Bromide therapy for pediatric seizure disorder intractable to other antiepileptic drugs. J Child Neurol, 5:65-7.
213. Wyllie E, Lachhwani DK, Gupta A, et al. 2007. Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings. Neurology, 69:389-97.
214. Xu X, Müller-Taubenberger A, Adley KE, et al. 2007. Attenuation of Phospholipid Signaling Provides a Novel Mechanism for the Action of Valproic Acid. Eukariotic Cell, 6:899-906.
215. Yagi K. 2004. Overview of Japanese experience, controlled and uncontrolled trials. Seizure, 13(S):S11-S15
216. Yamatogi Y, Ohtsuka Y, Ishida T, et al. 1979. Treatment of the Lennox syndrome with ACTH: a clinical and electroencephalographic study. Brain Dev, 1:267-76.
217. Yamatogi Y, Ohtahara S. 2006. Multiple independent spike foci and epilepsy, with special reference to a new epileptic syndrome of "severe epilepsy with multiple independent spike loci". Epilepsy Res, 70(S1):S96-S104.
218. Yildirim M, Marangoz C. 2006. Anticonvulsant effects of melatonin on penicillin-induced epileptiform activity in rats. Brain Res, 12,1099:183-8.
219. You SJ, Lee JK, Ko TS. 2007b. Epilepsy surgery in a patient with Lennox-Gastaut syndrome and cortical dysplasia. Brain Dev, 29:167-70.
220. You SJ, Kang HC, Ko TS, et al. 2007c. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox-Gastaut syndrome. Brain Dev, 30:195-9.
221. You S J, Kang HC, Kim HD, et al. 2008a. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev, 30:287-90.
222. You SJ, Jung DE, Kim HD, et al. 2008b. Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy. Eur J Paediatr Neurol, 12:314-20.
223. Zhao Q, Tian Z, Liu Z, et al. 2003. Evaluation of the combination of multiple subpial transection and other techniques for treatment of intractable epilepsy. Chin Med J (Engl), 116:101)4-7.